# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Preliminary SpotLight™ Human Lambda reagent data to be showcased by GSK at the 16th annual PEACe Conference EMERYVILLE, Calif....
Fully quantitative bulk and comprehensive single cell proteomics are now both available on the IsoSpark platform
TD Cowen analyst Steven Mah downgrades PhenomeX (NASDAQ:CELL) from Outperform to Market Perform and announces $1 price target.
Berenberg analyst Gaurav Goparaju downgrades PhenomeX (NASDAQ:CELL) from Buy to Hold and lowers the price target from $8 to $1.